ReviewInternational journal of molecular sciences2011
Nanotechnology and nanotoxicology in retinopathy.
Review in International journal of molecular sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 66 citations in OpenAlex.
- Emerging innovations in ophthalmic drug delivery for diabetic retinopathy: a translational perspective.Drug delivery and translational research · 2026Review
- Recent advancements in polymer science for retinal diseases: New frontiers in drug delivery systems.APL bioengineering · 2025Article
- Nanotherapy for Neural Retinal Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Chitosan as a promising materials for the construction of nanocarriers for diabetic retinopathy: an updated review.Journal of biological engineering · 2024Review
- Innovative Strategies for Drug Delivery to the Ocular Posterior Segment.Pharmaceutics · 2023Review
- Nanomedicine and drug delivery to the retina: current status and implications for gene therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- Metallic Engineered Nanomaterials and Ocular Toxicity: A Current Perspective.Pharmaceutics · 2022Review
- Emerging Theranostic Nanomaterials in Diabetes and Its Complications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Tissue Engineering Meets Nanotechnology: Molecular Mechanism Modulations in Cornea Regeneration.Micromachines · 2021Review
- Ocular Drug Delivery: Role of Degradable Polymeric Nanocarriers for Ophthalmic Application.International journal of molecular sciences · 2018Review
- A Novel Nanoparticle Mediated Selective Inner Retinal Photocoagulation for Diseases of the Inner Retina.IEEE transactions on nanobioscience · 2017Article
- Novel Strategies for the Improvement of Stem Cells' Transplantation in Degenerative Retinal Diseases.Stem cells international · 2016Review
- Nanoengineering of therapeutics for retinal vascular disease.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2015Review
- Nanomaterials-Tools, Technology and Methodology of Nanotechnology Based Biomedical Systems for Diagnostics and Therapy.Biomedicines · 2015Review
- Topical Ocular Drug Delivery to the Back of the Eye by Mucus-Penetrating Particles.Translational vision science & technology · 2015Article
- The functions and applications of RGD in tumor therapy and tissue engineering.International journal of molecular sciences · 2013Review
- Nanotechnology in ophthalmology.Indian journal of ophthalmology · 2013Article
- Gene therapy for Leber congenital amaurosis: advances and future directions.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2012Review
- Gene therapy in animal models of autosomal dominant retinitis pigmentosa.Molecular vision · 2012Review
- The utility and risks of therapeutic nanotechnology in the retina.Therapeutic advances in ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoparticles are nanometer-scaled particles, and can be utilized in the form of nanocapsules, nanoconjugates, or nanoparticles themselves for the treatment of retinopathy, including angiogensis-related blindness, retinal degeneration, and uveitis. They are thought to improve the bioavailability in the retina and the permeability of therapeutic molecules across the barriers of the eye, such as the cornea, conjunctiva, and especially, blood-retinal barriers (BRBs). However, consisting of multiple neuronal cells, the retina can be the target of neuronal toxicity of nanoparticles, in common with the central and peripheral nervous system. Furthermore, the ability of nanoparticles to pass through the BRBs might increase the possibility of toxicity, simultaneously promoting distribution in the retinal layers. In this regard, we discussed nanotechnology and nanotoxicology in the treatment of retinopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.